Search

A pilot study is being conducted to test the safety and effectiveness of combining pacritinib with a Bruton's tyrosine kinase (BTK) inhibitor in treating patients with relapsed or refractory mantle cell lymphoma. Pacritinib may inhibit tumor cell growth by blocking necessary enzymes, while BTK inhibitors target abnormal levels of BTK in B-cell cancers like mantle cell lymphoma. The study aims to assess the safety, tolerability, and efficacy of this combination treatment for patients with relapsed or refractory mantle cell lymphoma. [Extracted from the article]

The article discusses a Phase 1 clinical trial, NCT06667687, evaluating the safety, pharmacokinetics, and efficacy of ABBV-291 in adult participants with relapsed or refractory Non-Hodgkin's Lymphoma (NHL). The study aims to determine the maximum administered dose of ABBV-291 and assess its impact on disease activity. Approximately 165 adult participants with various NHL subtypes will be enrolled in the study, which involves dose escalation and expansion phases over a 74-month duration. Regular medical assessments, blood tests, and monitoring of side effects will be conducted throughout the trial. [Extracted from the article]

A study conducted at the University of Vermont focused on the transformation of splenic marginal zone lymphoma into large B-cell lymphoma, with a cyclin-d1 rearrangement as a secondary event in the process. The research highlighted a case of an elderly man with a TP53 deletion at diagnosis, later developing a CCND1 rearrangement at the time of relapse. This study is significant as it is the first report of this specific lymphoma progression. For more information, readers can refer to the article "cyclin-d1 Rearrangement As a Secondary Event In the Large Cell Transformation of Splenic Marginal Zone Lymphoma With a tp53 Deletion" published in Virchows Archiv. [Extracted from the article]

Researchers at Hospital do Cancer de Muriae conducted a study comparing the outcomes of patients with lymphoma who received a conditioning regimen with Lomustine, Etoposide, and Cyclophosphamide (LEC) for autologous stem cell transplantation to those who underwent another regimen (CBV). The study found that the LEC protocol was safe and showed higher overall survival rates at 24 months compared to the CBV group. However, due to a shortage of lomustine and carmustine in Brazil, new alternative protocols will be necessary. This research provides valuable insights into effective treatment options for patients with lymphoma. [Extracted from the article]

A recent study conducted at Nagano Red Cross Hospital in Japan focused on a rare disorder called acquired amegakaryocytic thrombocytopenia (AAMT) in a patient with mantle cell lymphoma. The research highlighted the challenges in diagnosing and treating this condition, which involves severe thrombocytopenic bleeding and platelet destruction. The study concluded that AAMT and immune thrombocytopenia (ITP) can overlap as part of a broader spectrum of platelet-related autoimmune diseases. This peer-reviewed research sheds light on the complexities of managing such conditions and the potential benefits of multiagent chemotherapy in treating both thrombocytopenia and mantle cell lymphoma. [Extracted from the article]

Researchers have submitted a patent application for "Stable Anti-Cd79b Immunoconjugate Formulations" to the USPTO, aiming to address challenges in administering biologics via IV infusion bags. The patent application focuses on developing a stable pharmaceutical composition containing an anti-CD79b immunoconjugate and a surfactant to maintain stability during storage and IV administration. The formulation includes specific concentrations of the immunoconjugate, surfactant, buffering agent, and sugar to ensure stability and efficacy in treating proliferative disorders, particularly B cell proliferative disorders like lymphoma and leukemia. The patent application provides detailed information on the composition, concentration ranges, and methods for administering the pharmaceutical composition. [Extracted from the article]

A patent has been issued for methods of treating non-Hodgkin lymphoma using a specific compound, with the aim of addressing the limitations and side effects associated with current cancer therapies such as surgery, chemotherapy, and radiation. Non-Hodgkin lymphoma is a common cancer affecting both men and women, with various subtypes like diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and primary central nervous system lymphoma. The patent outlines specific methods of treatment for relapsed or refractory cases of these lymphomas, emphasizing the need for novel therapeutic approaches to improve patient outcomes. [Extracted from the article]

A recent study conducted by researchers at Bern University Hospital in Switzerland focused on the use of CAR-T cell therapy for patients with relapsed/refractory mantle cell lymphoma. The study found that CAR-T cell treatment improved survival rates for these patients. However, the researchers also reported a case of a patient who developed acute erythroid leukemia with TP53 inactivation 26 months after CAR-T therapy. The study suggests that secondary malignancies may be more frequent after CAR-T therapies, and further research is needed to assess the long-term toxicities of these treatments. [Extracted from the article]

A report from the University of Miami discusses the findings of a study on mantle cell lymphoma (MCL), a type of cancer that is often diagnosed at advanced stages and has historically had a poor prognosis. The study focuses on four patients with stage IV MCL who experienced relapse in the form of soft tissue tumors in their extremities. The average time to relapse was 99 months following the initial diagnosis. The researchers emphasize the importance of healthcare providers being aware of soft tissue lesions as a potential sign of MCL relapse. [Extracted from the article]

A recent study conducted by researchers from Kagawa University in Takamatsu, Japan, focused on Progressive Multifocal Leukoencephalopathy (PML) in a patient who had completed chemotherapy for mantle cell lymphoma. The study found that 18F-THK5351 Positron Emission Tomography (PET) was more effective than brain magnetic resonance imaging (MRI) in detecting PML lesions. The researchers concluded that 18F-THK5351 PET, which captures fresh PML lesions better than MRI, may be a valuable tool in diagnosing and monitoring PML. This research has been peer-reviewed and provides important insights into the detection and understanding of PML. [Extracted from the article]

A study conducted by researchers at Oxford University Hospitals NHS Foundation Trust has found that pirtobrutinib, a noncovalent Bruton tyrosine kinase inhibitor (BTKi), shows promise in treating mantle cell lymphoma (MCL) patients who have been previously treated with covalent BTKi. The study involved 90 patients with relapsed/refractory MCL who received pirtobrutinib monotherapy. The overall response rate was 57.8%, with a median duration of response of 21.6 months. The drug was well-tolerated, with low rates of treatment discontinuation due to side effects. This research suggests that pirtobrutinib could be an effective treatment option for heavily pretreated MCL patients. [Extracted from the article]

A recent study conducted at the University of Verona in Italy examined the effectiveness of different treatment regimens for mantle cell lymphoma (MCL). The researchers found that bendamustine-rituximab (BR) followed by rituximab maintenance (R) was an effective induction regimen, particularly for older patients. The study also found that the addition of bortezomib or lenalidomide to the treatment did not improve progression-free survival and was associated with increased risks of neutropenia and other adverse events. This research provides valuable insights into the optimal treatment options for MCL patients. [Extracted from the article]

A recent study conducted at the Cleveland Clinic examined the use of CD20 monoclonal antibodies in the treatment of mantle cell lymphoma (MCL). The study aimed to determine if the addition of bortezomib to bendamustine plus rituximab (BR) induction, and/or the addition of lenalidomide to rituximab (LR) maintenance, would improve progression-free survival (PFS) in treatment-naive MCL patients. The results showed that the addition of bortezomib did not prolong PFS, and the addition of lenalidomide did not significantly improve PFS. However, the study concluded that BR followed by rituximab maintenance is an effective initial therapy for older patients with MCL. [Extracted from the article]

A recent report from the Dana-Farber Cancer Institute in Boston, Massachusetts discusses the challenges in treating relapsed or refractory mantle cell lymphoma (MCL). While there have been advancements in non-Hodgkin lymphoma treatment, effective management of R/R MCL remains difficult. The development of Bruton tyrosine kinase (BTK) inhibitors has improved treatment options, but they are not curative. The report reviews various treatment strategies, including BTK inhibitors, venetoclax, lenalidomide-based regimens, and chimeric antigen receptor T-cell therapy, as well as promising novel agents. The research highlights the need for continued exploration of targeted agents to improve outcomes for R/R MCL. [Extracted from the article]

A recent study conducted at Ludwig-Maximilians-University Munich examined the incidence and association of immune effector cell-associated hematotoxicity (ICAHT) after CAR-T therapy for refractory B-cell malignancies. The study found that the novel EHA/EBMT consensus grading system for ICAHT was strongly associated with the duration of severe neutropenia, the presence of cytopenias, and the use of transfusions. Patients with severe ICAHT had a higher rate of severe infections, increased nonrelapse mortality, and inferior survival outcomes. The study concluded that the novel grading system is clinically relevant and should be used in clinical trials evaluating CAR-T therapies. [Extracted from the article]

A recent study conducted at Juntendo Nerima Hospital in Tokyo, Japan, focused on mantle cell lymphoma (MCL) and its manifestation in the sphenoid sinus. The study reported a case of a 57-year-old man who initially presented with a mass in the sphenoid sinus and subsequently developed rapid growth of a testicular mass. The patient experienced visual disturbances and bilateral visual loss after urological surgery, leading to a diagnosis of MCL in the testis and sphenoid sinus. Treatment with corticosteroids and chemotherapy resulted in the recovery of the patient's left vision, while his right vision remained lost. This case represents the first reported instance of MCL in the sphenoid sinus causing bilateral blindness and subsequent recovery on one side. [Extracted from the article]

This article provides information about a newly launched clinical trial in China for a drug called YK012, which is being tested in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). The trial aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of YK012, and it is the first-in-human trial for this drug. The study will involve administering YK012 to patients through intravenous infusion every two weeks for a treatment cycle of four weeks. The primary outcome measures include assessing adverse events, dose-limiting toxicity, and determining the maximum tolerated dose for further clinical trials. The trial is currently recruiting participants, with a target enrollment of 48 individuals, and the primary investigator is Yuankai Shi from the Cancer Institute and Hospital, Chinese Academy of Medical Sciences. [Extracted from the article]

A clinical trial, NCT06572618, is currently underway to test the effectiveness of nemtabrutinib in combination with rituximab for the treatment of mantle cell lymphoma. Nemtabrutinib is a kinase inhibitor that targets a protein called BTK, which is found in B-cell cancers like mantle cell lymphoma. Rituximab is a monoclonal antibody that binds to a protein called CD20, potentially aiding the immune system in killing cancer cells. The trial aims to assess various outcomes, including response rates, survival rates, and duration of response, in patients receiving this combination therapy. Additionally, the document provides alternative names for medical procedures and drugs, such as bone marrow biopsies, Nemtabrutinib, positron emission tomography and computed tomography scans, and Rituximab. It also offers information about a clinical trial for Rituximab, which is not yet recruiting participants and plans to enroll 27 individuals. The trial is open to people of all genders aged 18 and above who have been diagnosed with mantle cell lymphoma and require treatment with no prior systemic anticancer therapies. The study is a collaboration between the City of Hope Medical Center and the National Cancer Institute. [Extracted from the article]

A study conducted at the City of Hope National Medical Center in Duarte, California, has found that adding venetoclax to the combination of lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma (MCL). The study enrolled 28 patients with untreated MCL and found that the overall response rate was 96% and the complete response rate was 86%. Additionally, 86% of patients achieved minimal residual disease undetectability. The combination of lenalidomide, rituximab, and venetoclax was well-tolerated, with neutropenia and thrombocytopenia being the most common adverse events. The study concluded that this regimen is a safe and effective treatment option for patients with untreated MCL. [Extracted from the article]

A patent has been issued for inhibitors of Bruton's tyrosine kinase (BTK) and their use in treating cancer. The patent, assigned to Janssen Pharmaceutica NV, describes compounds that can be administered to patients with mantle cell lymphoma, chronic lymphocytic leukemia, macroglobulinemia, or multiple myeloma. BTK is a protein that plays a role in the growth and differentiation of blood and endothelial cells. The compounds described in the patent have the potential to modulate biology associated with B cells, macrophages, mast cells, osteoclasts, and platelet microparticles. [Extracted from the article]

The article highlights a U.S. patent filed by inventors at Tel-Aviv University Ltd. in Israel for targeted lipid-based nanoparticles designed for the efficient delivery of RNAi molecules, such as siRNA, to leukocytes, specifically B-cells and T-cells, for the treatment of diseases like lymphoma, leukemia, and multiple myeloma. It explains how these nanoparticles, functionalized with antibodies like anti-CD4 and anti-CD38, enable precise gene silencing in difficult-to-transfect immune cells.

The article reports on a case study from China Medical University involving a patient with both Warthin tumor (WT) and mantle cell lymphoma (MCL). Topics include the rarity of this dual diagnosis, the diagnostic challenges, and the importance of thorough examination of lymphoid stroma in WT to detect concurrent lymphoma.

The article reports that JW Therapeutics has received approval from the National Medical Products Administration (NMPA) in China for the supplemental Biological License Application (sBLA) of Carteyva® for treating adult patients with relapsed or refractory Mantle Cell Lymphoma (r/r MCL). Topics include the efficacy and safety of Carteyva®, its status as the first CAR-T cell therapy for r/r MCL in China, and the ongoing need for effective treatments for this cancer.

A recent study conducted by researchers at the John Theurer Cancer Center in Hackensack, New Jersey, has provided new data on the treatment of mantle cell lymphoma (MCL). The study found that progress has been made in improving outcomes for MCL patients, particularly through the use of combination therapy and autologous stem cell transplantation. The research also highlighted the heterogeneity of MCL at the molecular level, which explains the differences in clinical behavior and response to therapy. The study concluded that ongoing and future work will continue to improve the management and outcomes for all MCL patients. [Extracted from the article]

A recent study from the Department of Immunology Genetics and Pathology discusses the use of Bruton's tyrosine kinase inhibitors (BTKi) in patients with mantle cell lymphoma (MCL). While side effects are usually manageable, the study presents two cases of life-threatening aplastic anemia (AA) in patients treated with the BTKi acalabrutinib. One patient died from a neutropenic infection, while the other experienced a relapse of MCL after successful immunosuppressive treatment. The study concludes that AA should be considered as a potentially fatal complication in patients receiving BTKi treatment. [Extracted from the article]

This document provides information about a clinical trial, NCT06561425, that is currently recruiting participants to evaluate the feasibility, safety, and efficacy of an experimental treatment called GLPG5101 in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). The trial aims to determine the optimal dose of GLPG5101 with the fewest side effects in the first phase, and in the second phase, all participants will receive the best dose identified. The trial will assess various outcome measures, including adverse events, objective response, duration of response, and survival rates. The trial is open to individuals with aggressive DLBCL, FL, MZL, MCL, BL, PCNSL, relapsed or refractory disease, and adequate bone marrow, renal, hepatic, and pulmonary function. The trial is being conducted in the United States, Belgium, and the Netherlands, and contact information for further inquiries is provided. [Extracted from the article]

The article focuses on a Phase 2, open-label, randomized clinical trial evaluating the combination of pirtobrutinib and brexucabtagene autoleucel in patients with relapsed or refractory mantle cell lymphoma. Topics include the study design and goals, which involve assessing progression-free survival and comparing the efficacy and safety of concurrent pirtobrutinib versus no concurrent pirtobrutinib, as well as the secondary outcomes related to severe adverse events and overall response rates.

The article offers information on the clinical and pathological characteristics of blastoid mantle cell lymphoma (B-MCL). Topics discussed include the diagnostic challenges posed by B-MCL due to its aggressive nature and inconsistent immunohistochemistry; the clinical and histopathological findings from a study of 12 cases; and the comparison of survival outcomes and treatment responses between B-MCL patients and those with classic mantle cell lymphoma.

The article present a case study of a 73-year-old female patient with priors of a mantle cell lymphoma (MCL), diagnosed 9 months ago, treated with chemotherapy, and currently with maintenance rituximab therapy, and a total knee replacement on the left leg 1 year ago. Topics discussed include the clinical presentation of MCL with skin lesions; the diagnostic approach using skin biopsy and immunohistochemistry; and the treatment outcomes including radiotherapy and ongoing chemotherapy.

The article from Dana-Farber Cancer Institute discusses new research on mantle cell lymphoma (MCL). Topics include the long-term follow-up results of the LYMA101 clinical trial, the use of obinutuzumab showing superior outcomes compared to rituximab in terms of minimal residual disease negativity, progression-free survival, and overall survival, and the implications of these findings for potential changes in frontline treatment strategies for MCL.

A patent has been issued for salts of a Pim kinase inhibitor by the inventors Cao, Ganfeng et al. The patent, assigned to Incyte Corporation, focuses on the overexpression of Pim kinases in various types of cancers and the potential therapeutic benefits of inhibiting these kinases. The invention describes new forms of Pim-inhibiting molecules, including salts and crystalline forms, which could be used to develop safe and effective drug products. This patent provides valuable information for researchers and biopharmaceutical companies working in the field of cancer treatment. [Extracted from the article]

A recent study conducted at the University of Pennsylvania examined the use of bendamustine as an alternative to standard cyclophosphamide/fludarabine lymphodepletion therapy in the treatment of mantle cell lymphoma (MCL) with brexucabtagene autoleucel (brexu-cel), a chimeric antigen receptor (CAR) T-cell therapy. The study found that bendamustine was a feasible and safe option, with comparable outcomes to the standard therapy. The research also observed CAR T-cell expansion and persistence after bendamustine lymphodepletion. These findings provide new insights into the treatment of MCL and offer potential alternatives for patients. [Extracted from the article]

A report from Jamia Hamdard in New Delhi, India discusses the role of ibrutinib in cancer therapy. B-cell receptor (BCR) activation is an important step in the progression of B-cell cancer, and BCR signaling requires Bruton's tyrosine kinase (BTK). Ibrutinib is a medication that inhibits BTK and has been authorized for second-line therapy for certain types of lymphoma. Nano formulations of ibrutinib, such as nanoparticles composed of chitosan and sulfobutylether ether-b-cyclodextrin, have been developed to improve its bioavailability. The research combines clinical outcomes and side effects of ibrutinib from various trials. [Extracted from the article]

A recent report from Uppsala University in Sweden discusses the advancements in treatments for mantle cell lymphoma (MCL) and the increased susceptibility to infections among survivors. The study found that the infection rate among MCL patients was twice as high compared to a control group, with a notable increase in infection rates starting four years before MCL diagnosis. Influenza, pneumonia, bacterial infections, urinary tract infections, and acute upper respiratory infections were the most common infections experienced by MCL patients. The study emphasizes the importance of assessing infectious morbidity when evaluating new treatments for MCL. Further research is needed to explore strategies for reducing the burden of infectious diseases in MCL patients. [Extracted from the article]

A recent report from Hunan Normal University in the People's Republic of China discusses a rare case of mantle cell lymphoma (MCL) in the gastrointestinal tract. MCL in the gastrointestinal tract is uncommon, accounting for only 4-9% of reported cases of gastrointestinal non-Hodgkin lymphoma. The report describes a patient with MCL characterized by numerous diffuse polypoid lesions throughout the digestive tract. The patient initially received a treatment regimen of rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone, which was later changed to rituximab combined with etoposide, oxaliplatin, ifosfamide, and ibrutinib capsules. The research concludes that while MCL has a poor prognosis, complete response can be achieved with treatment. [Extracted from the article]

This document provides information about a clinical trial being conducted in China for the treatment of mantle cell lymphoma (MCL). The trial aims to investigate the efficacy and safety of a combination treatment involving the drugs zanubrutinib, lenalidomide, obinutuzumab, and cytarabine, along with CAR-T therapy. The trial is not yet recruiting and plans to enroll 39 participants. The primary completion date for data collection is December 31, 2026. The trial is being conducted by the Institute of Hematology & Blood Diseases Hospital in China. [Extracted from the article]

A recent study conducted by the Chinese Academy of Sciences has revealed new insights into the development of mantle cell lymphoma (MCL). The researchers discovered that the disruption of cyclin D1 degradation plays a crucial role in the development of MCL. They also found that arsenic trioxide (ATO) can enhance the degradation of cyclin D1, leading to apoptosis in MCL cells. This study provides valuable information on the mechanisms of MCL tumor development and offers a potential new strategy for MCL treatment. [Extracted from the article]

A recent study conducted by the Center for Interdisciplinary Research and Innovation (CIRI-AUTH) in Thessaloniki, Greece, has provided new insights into mantle cell lymphoma (MCL), a rare and aggressive form of B-cell non-Hodgkin lymphoma. The study focused on the pathobiology, diagnosis, and treatment of MCL using network-based and drug-repurposing approaches. The researchers discovered that a small set of initially differentially expressed genes in MCL rapidly expanded into numerous deregulated cellular processes and signaling pathways as the disease progressed. The study also identified potential diagnostic and prognostic biomarkers, drug targets, and combination therapies for MCL. Further research is recommended to validate these findings for their clinical impact. [Extracted from the article]

A study conducted at Uppsala University has found that patients with mantle cell lymphoma (MCL) are at a higher risk of infections. MCL is a rare and incurable type of cancer that mainly affects men over the age of 70. The study compared infection rates in MCL patients to a reference group and found that MCL patients had twice as many infections. The higher infection rate persisted for up to eight years after diagnosis. The researchers emphasize the need for strategies to manage and reduce the risk of infections in MCL patients to improve their overall quality of life. [Extracted from the article]

A recent study conducted by researchers at the University of Virginia examined the potential benefits of rituximab maintenance (RM) after first-line bendamustine and rituximab (BR) treatment in patients with mantle cell lymphoma (MCL). The study analyzed a large observational cohort of MCL patients from 26 US academic centers who received BR as their initial treatment. The results showed that RM after BR was associated with improved event-free survival (EFS), EFS2, and overall survival (OS) in patients with MCL. These findings support the use of RM in routine practice for newly diagnosed MCL patients. [Extracted from the article]

A clinical trial, NCT06482684, is currently underway in Germany to study the use of CAR-T-cell treatment for untreated high-risk Mantle Cell Lymphoma (MCL). The trial involves an abbreviated induction phase with Rituximab and Ibrutinib, followed by CAR-T-cell treatment and maintenance with Ibrutinib. The goal of the trial is to compare the effectiveness, safety, and tolerability of this treatment approach with conventional immunochemotherapy and Ibrutinib. The trial is recruiting participants and is regulated by the U.S. FDA. Contact information for the trial is provided. [Extracted from the article]

The patent application titled "Pharmaceutical Compositions Of Mosunetuzumab And Methods Of Use" discusses the development of a pharmaceutical composition for mosunetuzumab, a drug used in the treatment of cancer, specifically lymphoma. The composition includes specific concentrations of ingredients such as polysorbate 20, methionine, buffering agents, and tonicity agents, with the pH also specified. The application provides detailed information about the concentrations and ratios of these ingredients, as well as stability and purity requirements for the compositions. The compositions are intended for use as drug products and have a shelf-life of at least 36 months when stored properly. [Extracted from the article]

New research from Memorial Sloan Kettering Cancer Center (MSK) has led to the development of a machine-learning tool called MRD-EDGE, which can detect minimal residual disease (MRD) in several types of cancer after surgery. The tool uses liquid biopsies to detect cancer mutations at low levels that other tests cannot pick up. The FDA has also approved a CAR T cell therapy called lisocabtagene maraleucel for mantle cell lymphoma, based on a study showing an 83% objective response rate. Additionally, a study has found that a blood test using machine learning can predict the likelihood of lung cancer and increase the chance of finding it through low-dose CT scans. Finally, researchers have discovered that the protein mTOR controls the breakdown of key metabolic enzymes, shedding new light on cellular metabolism. [Extracted from the article]

A recent study conducted at the University of Texas MD Anderson Cancer Center has revealed promising findings regarding the treatment of mantle cell lymphoma (MCL). The study focused on the development of resistance to current therapies, such as inhibitors of Bruton's tyrosine kinase (BTKi) and chimeric antigen receptor T-cell (CAR-T) therapy. Researchers discovered that targeting cyclin-dependent kinase 9 (CDK9) with the CDK9 inhibitor enitociclib showed potential in overcoming therapeutic resistance in MCL models. The study suggests that enitociclib could be a valuable addition to the treatment options for MCL patients. [Extracted from the article]

A new report from the University College London (UCL) Hospitals NHS Foundation Trust provides real-world data on the use of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory mantle cell lymphoma (MCL) in the United Kingdom. The study found that brexu-cel demonstrated impressive responses in patients who had failed previous treatments, with an overall response rate of 93% and a complete response rate of 67%. However, the analysis also highlighted a significant dropout rate due to disease progression and manufacturing issues, and non-relapse mortality events were a concern. Overall, the outcomes for patients in the UK were comparable to those seen in clinical trials and other real-world reports. [Extracted from the article]